Search

everythinglearnresearchcommunity

for

Search:↓

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

The user is starting Dutasteride mesotherapy and seeks advice on whether to apply the solution immediately after microneedling or wait 12-24 hours. They couldn't find instructions for first-timers.

The user tried pyrilutamide for hair loss and noticed reduced scalp itch and improved skin but stopped due to mild heart sensations. They plan to update after consistent use, noting improved sleep when applied at night.

The user switched from finasteride to dutasteride while continuing minoxidil, noting thicker and faster hair growth with minimal side effects. Other users discussed transitioning between these treatments, with some experiencing side effects like gynecomastia and erectile dysfunction.

The user shared their 6-month progress using Dutasteride .5 daily, RU 100mg once a day, and 15 mg oral Minoxidil for hair loss. They reported visible results, no side effects, and increased body hair, despite concerns from others about the high dosage and potential health risks.

Switching from spironolactone to bicalutamide caused severe hair shedding, despite using treatments like dutasteride, minoxidil, and estradiol injections. The user is experiencing androgenetic alopecia and is seeking solutions to stop the hair loss.

Minoxidil caused water retention and gastrointestinal issues for the user, which improved after stopping the medication. The user is now using finasteride and topical minoxidil, experiencing excessive urination and concerns about systemic absorption.

The conversation discusses the use of dutasteride (0.5 mg daily) for hair loss, with additional treatments like minoxidil, derma rolling, and nizoral shampoo. The user reports positive progress over two years with no significant side effects, emphasizing the importance of consistency and patience.

The user experienced severe side effects when using topical Dutasteride and RU58841 together and is considering using them at different times of the day. They are seeking advice on whether this approach might reduce side effects.

Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.

The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.

The half-life of Dutasteride is commonly stated as around 5 weeks, but some sources suggest it is 170 hours for men aged 20–49, with further information indicating it varies from 3 days to 5 weeks depending on the dose. The user is seeking clarity on these conflicting figures.

Breezula® (Clascoterone) showed promising results in a Phase 2 trial for treating hair loss, being as effective as Propecia with no serious side effects. It might be released between 2021-2022, and a related acne treatment with the same active ingredient could be used in the meantime.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

Pyrilutamide's 0.5% solution showed minimal improvement, while the 1% solution appears more promising but costly. The user is currently using finasteride and oral minoxidil and considering adding Pyrilutamide if effective and affordable.

An 18-year-old male stopped using finasteride due to side effects and plans to start topical dutasteride, considering it a potential solution with fewer side effects. He continues using minoxidil despite no noticeable results and is exploring other treatments like RU58841.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.

A user experienced hairline improvement after four weeks on 1.5mg dutasteride but had side effects like reduced libido and sensitive nipples. They plan to switch to finasteride to manage these side effects.

A 31-year-old male switched from finasteride to oral dutasteride (0.5mg, 2x a week) and uses liquid minoxidil daily for hair loss. He experienced shedding and regrowth but is considering increasing dutasteride to 3x a week due to concerns about hair density and ongoing issues.

User mixed RU58841 with stemoxydine, experienced no side effects. Mixing RU58841 with fluridil caused chest tightness.

A user is trying fluridil/topilutamide for hair loss and experiencing side effects like pain in the testicles and genital discomfort. They previously had adverse effects with finasteride, dutasteride, and RU58841, and are considering other treatments like topical dutasteride and spironolactone for maintenance before a hair transplant.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

The post discusses issues with Minoxidil BAILLEUL 5% Men, specifically sprayer clogging and crystallization in bottles. Recommendations include rinsing the sprayer and soaking the bottle in hot water to dissolve crystals, with calculations suggesting the product remains effective despite these issues.

The conversation discusses the potential release date of a hair loss treatment called Pyrilutamide. One user suggests it may be available in about 5 years.

A user ordered a topical dutasteride gel with tretinoin for hair loss after unsatisfactory results with minoxidil and finasteride. Another user shared their experience with the same product, noting its pleasant smell and feel but difficulty in application and uncertainty about its absorption and frequency of use.

A 23-year-old man with hair loss, despite using dutasteride, oral minoxidil, and RU58841, is considering bicalutamide for regrowth but is concerned about feminization. Alternatives like topical estrogen, JXL069, and spironolactone are discussed, with suggestions to explore thyroid levels and other potential underlying conditions.

The user experienced bladder and prostate discomfort after taking finasteride and stopped the medication, but symptoms returned upon resuming at a lower dose. The doctor suggested trying dutasteride as an alternative.

A 27-year-old male experienced hair thickening using a specialized pill containing Dutasteride and Minoxidil, despite taking it irregularly due to being away from home. He plans to resume a more regular dosing schedule for better results, as he noticed side effects like brain fog and decreased libido.